Debt to Capital Ratio: A measurement of a company's financial leverage, calculated as the company's long-term debt divided by its total capital. Calculated as: Total Long-Term Debt / (Total Long-Term Debt + Shareholders Equity)
SAB Biotherapeutics, Inc. (SABS) had Debt to Capital Ratio of 0.01 for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-18.87M |
|
-- |
|
-- |
|
$20.00M |
|
$-20.00M |
|
$1.13M |
|
$-18.87M |
|
$-18.87M |
|
$-18.87M |
|
$-18.87M |
|
$-18.87M |
|
$-18.87M |
|
$-20.00M |
|
$-19.23M |
|
53.56M |
|
53.56M |
|
$-0.35 |
|
$-0.35 |
|
| Balance Sheet Financials | |
$112.78M |
|
$13.81M |
|
$135.69M |
|
$248.47M |
|
$9.85M |
|
$3.08M |
|
$11.37M |
|
$21.22M |
|
$227.25M |
|
$227.25M |
|
$227.25M |
|
75.75M |
|
| Cash Flow Statement Financials | |
$-14.27M |
|
$-65.65M |
|
$89.92M |
|
$10.50M |
|
$20.52M |
|
$10.02M |
|
$5.46M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.45 |
|
-- |
|
-- |
|
|
Debt to Capital Ratio |
0.01 |
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-15.25M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-8.30% |
|
-8.30% |
|
-7.59% |
|
-8.19% |
|
$3.00 |
|
$-0.28 |
|
$-0.27 |
|